Abstract: The present invention relates to an anti-human ?9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ?9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening for a compound that inhibits the activity of human ?9 integrin.

Abstract: The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.

Abstract: The present invention provides humanized antibodies that immunospecifically recognize human ?9 integrin. Some of these antibodies inhibit the biological functions of the ?9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with ?9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

Abstract: The present invention addresses the problem of providing a novel substance capable of interfering with various functions of integrin ?4, and/or providing a novel substance capable of interfering with both integrin ?4 and integrin ?9. The present invention provides an integrin ?4 mutant peptide having one portion of the extracellular domain of human integrin ?4, and the like, and in concrete terms relates to a peptide and the like having the amino acid sequence of Sequence No. 4 through 9, and a pharmaceutical composition comprising as the active ingredient the same peptide.

Abstract: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

Abstract: The present invention relates to an anti-human ?9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ?9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening for a compound that inhibits the activity of human ?9 integrin.

Abstract: The present invention relates to: an antibody, particularly a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human ?9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening a compound which inhibits the activity of human ?9 integrin.

Abstract: The present invention relates to an anti-human ?9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ?9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening for a compound that inhibits the activity of human ?9 integrin.

Abstract: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

Abstract: The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.

Abstract: The present invention provides humanized antibodies that immunospecifically recognize human ?9 integrin. Some of these antibodies inhibit the biological functions of the ?9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with ?9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

Abstract: The present invention relates to: an antibody (particularly a monoclonal antibody), a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human ?9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; a method for screening a compound which inhibits the activity of human ?9 integrin; and the like.

Abstract: The present invention provides an anti-mouse ?9 integrin antibody, an anti-human ?9 integrin antibody, a hybridoma producing any of the antibodies, a method of producing any of the antibodies and the hybridoma, and a pharmaceutical composition comprising any of the antibodies. The anti-?9 integrin antibody of the present invention inhibits the ?9 integrin function thereby to exhibit therapeutic effects on cancer, e.g., the growth and metastasis of a cancer cell, and an inflammatory disease, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease and the like.

Abstract: The present invention provides an anti-mouse ?9 integrin antibody, an anti-human ?9 integrin antibody, a hybridoma producing any of the antibodies, a method of producing any of the antibodies and the hybridoma, and a pharmaceutical composition comprising any of the antibodies. The anti-?9 integrin antibody of the present invention inhibits the ?9 integrin function thereby to exhibit therapeutic effects on cancer, e.g., the growth and metastasis of a cancer cell, and an inflammatory disease, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease and the like.

Abstract: An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR sequence or sequence equivalent thereto to osteopontin or its fragment. This antibody is useful in remedies for autoimmune diseases, remedies for rheumatism and remedies for rheumatoid arthritis. Also, a method of treating autoimmune disease, rheumatism or rheumatoid arthritis is provided. This antibody is useful in diagnostics and a diagnostic method for rheumatism too.

Abstract: The invention relates to an immunocompetent cell activation inhibitor comprising an antibody against OPN or peptide fragment thereof; a therapeutic agent for diseases attributed to immunocompetent cell activation comprising this inhibitor as an active ingredient; and a method of treatment with the use of the therapeutic agent. The invention provides a medical agent capable of treating diseases attributed to immunocompetent cell activation, such as hepatopathy, asthma, arthritis, diabetes, lupus, multiple sclerosis, arteriosclerosis and lung fibrosis.

Abstract: A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.

Abstract: A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.

Abstract: An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR sequence or sequence equivalent thereto to osteopontin or its fragment. This antibody is useful in remedies for autoimmune diseases, remedies for rheumatism and remedies for rheumatoid arthritis. Also, a method of treating autoimmune disease, rheumatism or rheumatoid arthritis is provided. This antibody is useful in diagnostics and a diagnostic method for rheumatism too.